Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

‘Made In China’ Provision Removed From Green Channel Policy

This article was originally published in The Gray Sheet

Executive Summary

The original draft of an accelerated approval policy in China for innovative devices included a condition that a product being considered for the special pathway “is produced in China.” That condition has been removed from the latest draft following pressure from the U.S. government.

Advertisement

Related Content

Global View: Talking Harmonization And China With Jeffrey Gren
New China Fast-track Review Allows International Devices Accelerated Approval
Global View: Talking Harmonization And China With Jeffrey Gren
Seize China Opportunity Quickly, Morgan Stanley Analysts Urge
Chinese Leadership Transitions, But Health Care Reforms Expected To Move Forward As Planned
Medtronic Buys Kanghui To Expand Orthopedic Market Presence In China

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

MT032393

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel